Indeed, while CRC patients with wild type KRAS are eligible for targeted therapies with the anti-EGFR antibodies cetuximab or panitumumab, patients harboring KRAS mutations are excluded as mutations in KRAS are considered a predictive marker of resistance [14, 15]. The gene discussed is EGFR; the disease is colorectal carcinoma.